Investors & Media

~ 88% reduction in median Annualized Bleeding Rate (ABR) for all bleeds and 94% reduction in median ABR for spontaneous joint bleeds in highest dose tested ~ ~ SerpinPC observed to be well-tolerated ~ ~ Company has initiated planning for global registrational program ~ ~ Conference call and webcast

CAMBRIDGE, Mass. & LONDON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced today that Saurabh Saha, M.D., Ph.D., Chief Executive Officer, will participate in an analyst-led fireside chat at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference

~ Successful completion of an initial public offering of American Depositary Shares raising gross proceeds of $379.5 million to help advance portfolio of 16 clinical and preclinical programs ~ ~ Centessa leadership team strengthened through appointment of key industry executives ~ ~ Programs across

CAMBRIDGE, Mass. and LONDON, June 07, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced today that Saurabh Saha, M.D., Ph.D., Chief Executive Officer, will participate in an analyst-led fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on

CAMBRIDGE, Mass. and LONDON, June 04, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (“Centessa”), a clinical-stage company employing its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients, announced today that, in connection

CAMBRIDGE, Mass. & LONDON --(BUSINESS WIRE)--May 27, 2021-- Centessa Pharmaceuticals plc (“Centessa”), a clinical-stage company employing its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients, announced today the pricing of its

New Appointments Bring Expertise and Proven Leadership to Support Asset‐Centric R&D Model and Portfolio Advancement CAMBRIDGE, Mass. & LONDON, May 17, 2021 – Centessa Pharmaceuticals (“Centessa”) today announced key additions to its leadership team and Board of Directors.

CAMBRIDGE, Mass. & LONDON, May 10, 2021 – Centessa Pharmaceuticals (“Centessa”) today announced that Antoine Yver, M.D., M.Sc., has been appointed as Chief Medical Officer. Dr. Yver is one of the world’s leading drug developers with more than 30 years of global experience in the pharmaceutical

CAMBRIDGE, Mass. & LONDON--( BUSINESS WIRE )--Centessa Pharmaceuticals (“Centessa”), a pharmaceutical company consisting of 10 subsidiary companies advancing a portfolio of high conviction programs with strong biological validation, today announced key additions to its leadership team.

Merger of 10 Privately Held Biotech Companies with Highly Validated Programs Led by Industry Leading Teams to Operate Under Centessa Umbrella Company Founded by Medicxi with Financing Led by General Atlantic, and Co-led by Vida Ventures and Janus Henderson Investors Saurabh Saha, M.D., Ph.D.,